GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Belite Bio Inc ADR BLTE · USD

Health Care · US listing · 🇺🇸 United States

Compare

157.69

+2.27%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Belite Bio Inc ADR

Its shares trade under the ticker BLTE. It has been listed since 29 April 2022.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
29 Apr 2022
Employees
41
Head office
12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA, 92130
Incorporated in
E9
Classification
Pharmaceutical Preparations
Filer status
Large accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Belite Bio's lead product Tinlarebant is in phase 3 clinical trials for Stargardt disease type 1 in the US.
  • LBS-009 targets liver disease and gout with oral therapy in preclinical development.
  • The company operates as a subsidiary of Lin Bioscience International Ltd with 41 employees.

Weaknesses

  • Belite Bio has only one lead product candidate in phase 3 clinical trials.
  • The company's preclinical development stage for LBS-009 may face delays.
  • Limited employee count of 41 may impact R&D capacity.

Opportunities

  • Stargardt disease type 1 and geographic atrophy patients represent a significant market in the US.
  • LBS-009's potential for non-alcoholic fatty liver disease could expand market reach.
  • Phase 3 trials completion may lead to FDA approval and market entry.

Threats

  • Competition from other biopharmaceutical companies in the Health Care sector.
  • Regulatory hurdles could delay FDA approval for Tinlarebant.
  • Clinical trial failures might affect the company's development pipeline.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.